Macelignan attenuates activations of mitogen-activated protein kinases and nuclear factor kappa B induced by lipopolysaccharide in microglial cells

Biological and Pharmaceutical Bulletin

Volumn 32, Issue 6, 2009, Pages 1085-1090

  Ma, Jinhua ^a   Hwang, Yoo Kyeong ^a   Cho, Woo Hyun ^a   Han, Seol Heui ^b   Hwang, Jae Kwan ^c   Han, Jung Soo ^a  

^a Konkuk University   (South Korea)

^b Konkuk University Hospital   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Alzheimer's disease; Anti inflammation; Macelignan; Microglia; Mitogen activated protein kinase; Nuclear factor kappa B

Indexed keywords

ANTIINFLAMMATORY AGENT; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MACELIGNAN; MITOGEN ACTIVATED PROTEIN KINASE; MYRISTICA FRAGRANS EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN; CELL COUNT; ENZYME DEGRADATION; HIPPOCAMPUS; INFLAMMATION; MICROGLIA; MOUSE; NONHUMAN; NUTMEG; PLANT SEED; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CELL LINE; CELL NUCLEUS; CELL SURVIVAL; CYTOPLASM; LIGNANS; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASES; MYRISTICA FRAGRANS; NF-KAPPA B; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 66549122631     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.32.1085     Document Type: Article

References (34)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G. M., Cooper N. R., Eikelenboom P., Emmerling M., Fiebich B. L., Finch C. E., Frautschy S., Griffin W. S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I. R., McGeer P. L., O'Banion M. K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F. L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T., Neurobiol. Aging, 21, 383-421 (2000).
2. McGeer E. G., McGeer P. L., Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, 741-749 (2003).
3. Kreutzberg G. W., Trends Neurosci., 19, 312-318 (1996).
4. Giulian D., Haverkamp L. J., Yu J. H., Karshin W., Tom D., Li J., Kirkpatrick J., Kuo L. M., Roher A. E., J. Neurosci., 16, 6021-6037 (1996).
5. Zielasek J., Hartung H. P., Adv. Neuroimmunol., 6, 191-1122 (1996).
6. Meda L., Cassatella M. A., Szendrei G. I., Otvos L. Jr., Baron P., Villalba M., Ferrari D., Rossi F., Nature (London), 374, 647-650 (1995).
7. Sadhu S. K., Okuyama E., Fujimoto H., Ishibashi M., Chem. Pharm. Bull., 51, 595-598 (2003).
8. Jin D. Q., Lim C. S., Hwang J. K., Ha I., Han J. S., Biochem. Biophys. Res. Commun., 331, 1264-1269 (2005).
9. Cui C. A., Jin D. Q., Hwang Y. K., Lee I. S., Hwang J. K., Ha I., Han J. S., Neurosci. Lett., 448, 110-114 (2008).
10. Haddad J. J., Prog. Neurobiol., 73, 359-377 (2004).
11. Woo W., Shin K., Wagner H., Lotter H., Phytochemistry, 26, 1542-1543 (1987).
12. Kang J., Park E. J., Jou I., Kim J. H., Joe E. H., Neuroreport, 12, 1449-1452 (2001).
13. Jiang Y., Chen G., Zheng Y., Lu L., Wu C., Zhang Y., Liu Q., Cao X., Mol. Immunol., 45, 1557-1566 (2008).
14. Baeuerle P. A., Henkel T., Annu. Rev. Immunol., 12, 141-179 (1994).
15. Ghosh S., Karin M., Cell, 109 (Suppl.), S81-S96 (2002).
16. Moon D. O., Park S. Y., Lee K. J., Heo M. S., Kim K. C., Kim M. O., Lee J. D., Choi Y. H., Kim G. Y., Int. Immunopharmacol., 7, 1092-1101 (2007).
17. Imbe H., Okamoto K., Aikawa F., Kimura A., Donishi T., Tamai Y., Iwai-Liao Y., Senba E., Brain Res., 1134, 131-139 (2007).
18. Jin D. Q., Sung J. Y., Hwang Y. K., Kwon K. J., Han S. H., Min S. S., Han J. S., Pharmacol. Biochem. Behav., 89, 404-411 (2008).
19. Koistinaho M., Koistinaho J., Glia, 40, 175-183 (2002).
20. Pyo H., Jou I., Jung S., Hong S., Joe E. H., Neuroreport, 9, 871-874 (1998).
21. Wesselborg S., Bauer M. K., Vogt M., Schmitz M. L., Schulze-Osthoff K., J. Biol. Chem., 272, 12422-12429 (1997).
22. Hidding U., Mielke K., Waetzig V., Brecht S., Hanisch U., Behrens A., Wagner E., Herdegen T., Biochem. Pharmacol., 64, 781-788 (2002).
23. Waetzig V., Czeloth K., Hidding U., Mielke K., Kanzow M., Brecht S., Goetz M., Lucius R., Herdegen T., Hanisch U. K., Glia, 50, 235-246 (2005).
24. Waetzig V., Herdegen T., Neurosci. Lett., 361, 64-67 (2004).
25. Kuprash D. V., Udalova I. A., Turetskaya R. L., Rice N. R., Nedospasov S. A., Oncogene, 11, 97-106 (1995).
26. Siebenlist U., Franzoso G., Brown K., Annu. Rev. Cell Biol., 10, 405-455 (1994).
27. Petrova T. V., Akama K. T., Van Eldik L. J., Proc. Natl. Acad. Sci. U.S.A., 96, 4668-4673 (1999).
28. Ye S. M., Johnson R. W., J. Neuroimmunol., 117, 87-96 (2001).
29. Bauer M. K., Lieb K., Schulze-Osthoff K., Berger M., Gebicke-Haerter P. J., Bauer J., Fiebich B. L., Eur. J. Biochem., 243, 726-731 (1997).
30. Xie Q. W., Kashiwabara Y., Nathan C., J. Biol. Chem., 269, 4705-4708 (1994).
31. Park H. J., Son D. J., Lee C. W., Choi M. S., Lee U. S., Song H. S., Lee J. M., Hong J. T., Biochem. Pharmacol., 73, 237-247 (2007).
32. Han K. L., Choi J. S., Lee J. Y., Song J., Joe M. K., Jung M. H., Hwang J. K., Diabetes, 57, 737-745 (2007).
33. Sohn J. H., Han K. L., Kim J. H., Rukayadi Y., Hwang J. K., Biol. Pharm. Bull., 31, 273-277 (2008).
34. Heneka M. T., Landreth G. E., Hull M., Nat. Clin. Pract. Neurol., 3, 496-504 (2007).